DexCom (NASDAQ:DXCM) Receives News Sentiment Score of 0.15

News coverage about DexCom (NASDAQ:DXCM) has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DexCom earned a news impact score of 0.15 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 46.4430134585294 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

A number of equities research analysts have recently weighed in on the stock. Oppenheimer Holdings, Inc. set a $98.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Wednesday, May 3rd. Canaccord Genuity reduced their price target on shares of DexCom from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 3rd. BTIG Research downgraded shares of DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. B. Riley restated a “buy” rating and issued a $95.00 price target on shares of DexCom in a research note on Tuesday, May 2nd. Finally, BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Two analysts have rated the stock with a sell rating, three have given a hold rating and fifteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $87.00.

DexCom (NASDAQ DXCM) opened at 69.60 on Friday. DexCom has a 12 month low of $57.68 and a 12 month high of $96.38. The stock has a 50 day moving average of $71.12 and a 200-day moving average of $75.17. The firm’s market cap is $6.02 billion.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The business’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.24) earnings per share. Equities research analysts predict that DexCom will post ($0.77) earnings per share for the current fiscal year.

In other news, CEO Kevin R. Sayer sold 8,649 shares of the stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total transaction of $591,505.11. Following the completion of the sale, the chief executive officer now owns 347,329 shares of the company’s stock, valued at $23,753,830.31. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Andrew K. Balo sold 3,244 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $71.18, for a total value of $230,907.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,375 shares of company stock valued at $2,549,351. Insiders own 1.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit